Research programme: therapeutic agents - Epigen Biosciences
Latest Information Update: 29 Jul 2016
At a glance
- Originator Epigen Biosciences
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Unspecified
Highest Development Phases
- Research Unspecified
Most Recent Events
- 29 Jul 2016 Early research in Undefined indication in USA (unspecified route)
- 29 Jul 2016 Research programme: therapeutic agents - Epigen Biosciences is available for licensing as of 29 Jul 2016. http://www.epigenbiosciences.com/